X.T.L. Biopharmaceuticals Overview
Valuation check: XTLB's ROE is 404.33%, above the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow404.33%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
X.T.L. Biopharmaceuticals (XTLB) currently reports a ROE of 404.33%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore X.T.L. Biopharmaceuticals's ROE history and peer comparisons.
X.T.L. Biopharmaceuticals's ROE of 404.33% is higher than the Healthcare sector average of 29.33%. That is roughly 1278.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but X.T.L. Biopharmaceuticals's current 404.33% should be judged against Healthcare norms (sector average: 29.33%) and against XTLB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 404.33%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for X.T.L. Biopharmaceuticals, and consider following XTLB for alerts when major investors trade the stock.
X.T.L. Biopharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 404.33% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XTLB with unrelated industries.
